Veradermics, Inc MANE

Annual Quarterly

No quarterly revenue total was found in Veradermics, Inc's SEC filings.

Veradermics, Inc (MANE) files with the SEC under industry code 2834, Pharmaceutical Preparations. Free cash flow was -$14.5 million. As of Jun 30, 2026 it held $819.9 million in cash and investments and $428,000 in total debt.

Revenue
—
Net income
$-23.50M
+13.7% vs prior quarter
Operating cash flow
$-14.49M
+31.5% vs prior quarter
Free cash flow
$-14.51M
+31.4% vs prior quarter
EPS
$-0.58
+56.1% vs prior quarter
Dividend per share
None
Shares outstanding
41.78M
+0.0% vs prior quarter
Net cash
$819.47M
Q2 FY2026
Operating margin
—

Company profile

Industry
Pharmaceutical Preparations (SIC 2834)
Listed as
MANE (NYSE)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
New Haven, CT
SEC filer status
, Emerging growth company
SEC CIK
1827635

Other Pharmaceutical Preparations companies

All 570 Pharmaceutical Preparations companies

Key figures

Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.

Q2 FY2026
Jun 30, 2026
Q1 FY2026
Mar 31, 2026
Operating income
-$29.6M
-$29.9M
Net income
-$23.5M
-$27.2M
Diluted EPS
-$0.58
-$1.32
Operating cash flow
-$14.5M
-$21.2M
Free cash flow
-$14.5M
-$21.2M
Total assets
$825.7M
$397.4M
Total liabilities
$12.1M
$6.7M
Stockholders' equity
$813.6M
$390.6M
Cash and investments
$819.9M
$390.8M
Total debt
$428,000
$0

Recent SEC filings

Form Description Filed Period
8-K Current report
Regulation FD disclosure, Other events
 Oct 19, 2026 Oct 19, 2026
10-Q Quarterly report Aug 11, 2026 Jun 30, 2026
8-K Current report
Results of operations
 Aug 11, 2026 Aug 11, 2026
8-K Current report
Regulation FD disclosure, Other events
 Jul 15, 2026 Jul 15, 2026
10-Q Quarterly report May 12, 2026 Mar 31, 2026
8-K Current report
Results of operations
 May 12, 2026 May 12, 2026

All 97 Veradermics, Inc SEC filings

Source: SEC EDGAR filings. This is company-reported data, not investment advice.